These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 21226279)

  • 1. [Anti-inflammatory and immune modulation therapy against atherosclerosis].
    Yamashita T; Hirata K
    Nihon Rinsho; 2011 Jan; 69(1):168-72. PubMed ID: 21226279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulatory T cells and the control of modified lipoprotein autoimmunity-driven atherosclerosis.
    Nilsson J; Wigren M; Shah PK
    Trends Cardiovasc Med; 2009 Nov; 19(8):272-6. PubMed ID: 20447570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of oral tolerance to oxidized low-density lipoprotein ameliorates atherosclerosis.
    van Puijvelde GH; Hauer AD; de Vos P; van den Heuvel R; van Herwijnen MJ; van der Zee R; van Eden W; van Berkel TJ; Kuiper J
    Circulation; 2006 Oct; 114(18):1968-76. PubMed ID: 17060383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunosuppression in atherosclerosis: mobilizing the opposition within.
    Goronzy JJ; Weyand CM
    Circulation; 2006 Oct; 114(18):1901-4. PubMed ID: 17075023
    [No Abstract]   [Full Text] [Related]  

  • 5. Atheroprotective immunity and cardiovascular disease: therapeutic opportunities and challenges.
    Nilsson J; Lichtman A; Tedgui A
    J Intern Med; 2015 Nov; 278(5):507-19. PubMed ID: 25659809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging biomarkers and intervention targets for immune-modulation of atherosclerosis - a review of the experimental evidence.
    Björkbacka H; Fredrikson GN; Nilsson J
    Atherosclerosis; 2013 Mar; 227(1):9-17. PubMed ID: 23177975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apolipoprotein B100 autoimmunity and atherosclerosis - disease mechanisms and therapeutic potential.
    Nilsson J; Björkbacka H; Fredrikson GN
    Curr Opin Lipidol; 2012 Oct; 23(5):422-8. PubMed ID: 22814703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lymphocytes in atherosclerosis.
    Wigren M; Nilsson J; Kolbus D
    Clin Chim Acta; 2012 Oct; 413(19-20):1562-8. PubMed ID: 22565046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune-mediated mechanisms in atherosclerosis: prevention and treatment of clinical manifestations.
    Niessner A; Goronzy JJ; Weyand CM
    Curr Pharm Des; 2007; 13(36):3701-10. PubMed ID: 18220809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral anti-CD3 antibody treatment induces regulatory T cells and inhibits the development of atherosclerosis in mice.
    Sasaki N; Yamashita T; Takeda M; Shinohara M; Nakajima K; Tawa H; Usui T; Hirata K
    Circulation; 2009 Nov; 120(20):1996-2005. PubMed ID: 19884470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccination strategies in atherosclerosis.
    de Jager SC; Kuiper J
    Thromb Haemost; 2011 Nov; 106(5):796-803. PubMed ID: 22012002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inflammation and atherosclerosis: novel insights into plaque formation and destabilization.
    Stoll G; Bendszus M
    Stroke; 2006 Jul; 37(7):1923-32. PubMed ID: 16741184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral administration of recombinant Mycobacterium smegmatis expressing a tripeptide construct derived from endogenous and microbial antigens prevents atherosclerosis in ApoE(-/-) mice.
    Deshpande V; Krishnan R; Philip S; Faludi I; Ponnusamy T; Thota LN; Endresz V; Lu X; Kakkar VV; Mundkur LA
    Cardiovasc Ther; 2016 Oct; 34(5):314-24. PubMed ID: 27241889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulatory T Cell-Enhancing Therapies to Treat Atherosclerosis.
    Ait-Oufella H; Lavillegrand JR; Tedgui A
    Cells; 2021 Mar; 10(4):. PubMed ID: 33805071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antigen-tailored therapy based on the inflammatory theory of atherosclerosis.
    Harats D; George J
    Expert Rev Vaccines; 2004 Oct; 3(5):605-11. PubMed ID: 15485340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-term treatment with anti-CD3 antibody reduces the development and progression of atherosclerosis in mice.
    Steffens S; Burger F; Pelli G; Dean Y; Elson G; Kosco-Vilbois M; Chatenoud L; Mach F
    Circulation; 2006 Oct; 114(18):1977-84. PubMed ID: 17043169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccines modulating lipoprotein autoimmunity as a possible future therapy for cardiovascular disease.
    Nilsson J; Fredrikson GN; Björkbacka H; Chyu KY; Shah PK
    J Intern Med; 2009 Sep; 266(3):221-31. PubMed ID: 19702790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adaptive Response of T and B Cells in Atherosclerosis.
    Ketelhuth DF; Hansson GK
    Circ Res; 2016 Feb; 118(4):668-78. PubMed ID: 26892965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The potential role of preventing atherosclerosis by induction of neonatal tolerance to VLDL.
    Cui K; Hou G; Feng Y; Liang T; Kong F; Sun L; Wang S
    Cell Immunol; 2012; 272(2):290-2. PubMed ID: 22067889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxidized low-density lipoprotein-induced apoptotic dendritic cells as a novel therapy for atherosclerosis.
    Frodermann V; van Puijvelde GH; Wierts L; Lagraauw HM; Foks AC; van Santbrink PJ; Bot I; Kuiper J; de Jager SC
    J Immunol; 2015 Mar; 194(5):2208-18. PubMed ID: 25653425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.